表紙
市場調査レポート

アミロイドーシス:パイプライン製品の分析

Amyloidosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 192465
出版日 ページ情報 英文 141 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
アミロイドーシス:パイプライン製品の分析 Amyloidosis - Pipeline Review, H1 2016
出版日: 2016年02月29日 ページ情報: 英文 141 Pages
概要

アミロイドーシスとして知られる疾患群は、アミロイドタンパク質が体内の組織に異常に蓄積することから生じます。臓器の形状や機能に影響を与えるため、最終的に臓器不全に至ることもあります。素因として、L鎖と呼ばれる異常タンパク質のミスフォールディング、それに続く体内での蓄積が挙げられます。透析の結果、生じる場合もあります。症状は、倦怠感、胸痛、腫脹、呼吸障害などが見られます。治療には、移植、投薬 (利尿薬、化学療法薬) などが含まれます。

当レポートでは、アミロイドーシスに対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

目次

イントロダクション

アミロイドーシスの概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc
  • Bellus Health Inc.
  • Bsim2
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Isis Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Pfizer Inc.
  • ProteoTech, Inc.
  • Prothena Corporation Plc
  • SOM Innovation Biotech SL

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ALN-TTRsc02
  • Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis
  • carfilzomib
  • CLR-01
  • eprodisate disodium
  • GSK-2315698 + GSK-2398852
  • GSK-2398852
  • ixazomib citrate
  • LUNAR-101
  • LUNAR-102
  • Monoclonal Antibody for Amyloidosis
  • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy
  • NEOD-001
  • NPT-005
  • patisiran
  • pomalidomide
  • PTI-110
  • revusiran
  • Small Molecules for AL Amyloidosis
  • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy
  • tafamidis meglumine
  • tolcapone

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7646IDB

Summary

Global Markets Direct's, 'Amyloidosis - Pipeline Review, H1 2016', provides an overview of the Amyloidosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Amyloidosis
  • The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects
  • The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Amyloidosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Amyloidosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Amyloidosis Overview
  • Therapeutics Development
    • Pipeline Products for Amyloidosis - Overview
    • Pipeline Products for Amyloidosis - Comparative Analysis
  • Amyloidosis - Therapeutics under Development by Companies
  • Amyloidosis - Therapeutics under Investigation by Universities/Institutes
  • Amyloidosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Amyloidosis - Products under Development by Companies
  • Amyloidosis - Products under Investigation by Universities/Institutes
  • Amyloidosis - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Arcturus Therapeutics, Inc
    • Bellus Health Inc.
    • Bsim2
    • Celgene Corporation
    • GlaxoSmithKline Plc
    • Neurimmune Holding AG
    • NeuroPhage Pharmaceuticals, Inc.
    • Onyx Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Prothena Corporation Plc
    • SOM Innovation Biotech SL
    • Takeda Pharmaceutical Company Limited
  • Amyloidosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALN-ANG - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TTRsc02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLR-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eprodisate disodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2315698 + GSK-2398852 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-3039294 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • inotersen sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LUNAR-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LUNAR-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LUNAR-TTR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NEOD-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NI-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPT-005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • patisiran - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pomalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PTI-110 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • revusiran - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for AL Amyloidosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tafamidis meglumine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tolcapone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Amyloidosis - Recent Pipeline Updates
  • Amyloidosis - Dormant Projects
  • Amyloidosis - Product Development Milestones
    • Featured News & Press Releases
      • Feb 09, 2016: Data From Prothena Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology
      • Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
      • Jan 21, 2016: Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA for the Treatment of Orphan Disease AA Amyloidosis
      • Dec 17, 2015: Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
      • Nov 05, 2015: Prothena to Present New Preclinical Data for NEOD001 at 57th Annual American Society of Hematology Meeting
      • Nov 05, 2015: Prothena to Present New Preclinical Data for NEOD001 at 57th Annual American Society of Hematology Meeting
      • Nov 03, 2015: Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented at the EC-ATTR Meeting
      • Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Patisiran in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
      • Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
      • Oct 27, 2015: Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Amyloidosis, H1 2016
  • Number of Products under Development for Amyloidosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Amyloidosis - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Amyloidosis - Pipeline by Arcturus Therapeutics, Inc, H1 2016
  • Amyloidosis - Pipeline by Bellus Health Inc., H1 2016
  • Amyloidosis - Pipeline by Bsim2, H1 2016
  • Amyloidosis - Pipeline by Celgene Corporation, H1 2016
  • Amyloidosis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Amyloidosis - Pipeline by Neurimmune Holding AG, H1 2016
  • Amyloidosis - Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2016
  • Amyloidosis - Pipeline by Onyx Pharmaceuticals, Inc., H1 2016
  • Amyloidosis - Pipeline by Pfizer Inc., H1 2016
  • Amyloidosis - Pipeline by Prothena Corporation Plc, H1 2016
  • Amyloidosis - Pipeline by SOM Innovation Biotech SL, H1 2016
  • Amyloidosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Amyloidosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Amyloidosis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Amyloidosis, H1 2016
  • Number of Products under Development for Amyloidosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top